BeOne Medicines AG (FRA:49BA)
Germany · Delayed Price · Currency is EUR | Market Cap | 26.23B +18.3% |
| Revenue (ttm) | 4.95B +29.9% |
| Net Income | 462.91M |
| EPS | 3.92 |
| Shares Out | n/a |
| PE Ratio | 56.66 |
| Forward PE | 38.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 234.00 |
| Previous Close | 234.00 |
| Day's Range | 234.00 - 234.00 |
| 52-Week Range | 202.00 - 322.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
News
Baker Bros. Advisors LP Significantly Reduces Stake in BeOne Medicines Ltd
Baker Bros. Advisors LP Significantly Reduces Stake in BeOne Medicines Ltd
BeOne Medicines price target raised to $436 from $425 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $436 from $425 and keeps an Outperform rating on the shares. At ASCO, the company…
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company sai...
BeOne Medicines AG Transcript: Study update
Three solid tumor programs—CDK4 inhibitor in breast cancer, B7-H4 ADC in ovarian cancer, and GPC3x4-1BB bispecific in HCC—show strong efficacy and favorable safety, with all on track for registrational studies. The pipeline leverages rapid development and broad combinability.
BeOne Medicines AG Press release: Study update
BeOne Medicines AG issued a press release on June 1, 2026, disclosing material business information to investors.
BeOne Medicines AG Slides: Study update
BeOne Medicines AG has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients live 15% longer than BeOne Medicines' ...
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pi...
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic...
BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results
BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results
BeOne Medicines’ combination shows improved survival in adenocarcinoma
BeOne Medicines (ONC) announced data from the HERIZON-GEA-01 trial, published in The New England Journal of Medicine and to be presented at the ASCO Annual Meeting on June 1 in…
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were publish...
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 4...
China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index
Chinese AI firms MiniMax Group and Knowledge Atlas Technology – better known as Zhipu AI – will join the Hang Seng Tech Index next month. Their inclusion follows investor criticism that the city’s pri...
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematol...
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a ca...
BeOne Medicines price target raised to $367 from $364 at Leerink
Leerink raised the firm’s price target on BeOne Medicines (ONC) to $367 from $364 and keeps an Outperform rating on the shares. The firm notes the company announced that the…
BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi
BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has granted accelerated approval to Beqalzi, a next-generation BCL2 inhibitor, for the treatment of adult patients with relap...
US FDA approves BeOne's drug for a type of blood cancer
BeOne Medicines said on Wednesday that the U.S. Food and Drug Administration has approved its drug for a type of blood cancer.
BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Admi...
BeOne Medicines’ BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ...
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $395 from $389 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $409 from $405 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $409 from $405 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $420 from $410 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on BeOne Medicines (ONC) to $420 from $410 and keeps a Buy rating on the shares after the company reported a